Meridian Bioscience

Meridian Bioscience Change in Working Capital

The Change in Working Capital of Meridian Bioscience (VIVO) as of Oct 26, 2026 is 7.59 M USD. In the previous year, Change in Working Capital was -19.25 M USD — a change of -139.44% (higher).

Change in Working Capital

7.59 MUSD

YoY

-139.44%

Last updated:

Change in Working Capital of Meridian Bioscience is 2022 7.59 M USD. Change in Working Capital of Meridian Bioscience was 2021 -19.25 M USD. It decreases by -139.44% higher compared to the previous year.

The Meridian Bioscience Change in Working Capital history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Change in Working Capital
Date
Change in Working Capital
Jan 1, 2015
-2.64 M USD
Jan 1, 2016
-6.06 M USD
Jan 1, 2017
-780,000.00 USD
Jan 1, 2018
-860,000.00 USD
Jan 1, 2019
-1.24 M USD
Jan 1, 2020
-10.11 M USD
Jan 1, 2021
-19.25 M USD
Jan 1, 2022
7.59 M USD
The Meridian Bioscience Change in Working Capital history
YEARChange in Working CapitalYoY
7.59 MUSD-139.44%
-19.25 MUSD+90.40%
-10.11 MUSD+715.32%
-1.24 MUSD+44.19%
-860,000.00USD+10.26%
-780,000.00USD-87.13%
-6.06 MUSD+129.55%
-2.64 MUSD-63.18%
-7.17 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Meridian Bioscience Stock analysis

What does Meridian Bioscience do? Meridian Bioscience Inc. is a global company specializing in the development, manufacture, and distribution of test kits for the diagnosis of infectious diseases and other medical conditions. The company was founded in 1976 by William J. Motto and initially focused on the development of enzyme immunoassays (EIA). Over the years, the company has grown and diversified its product offerings, becoming a leading provider of diagnostic test kits for acute and chronic medical conditions, infectious diseases, gastrointestinal infections, and virology. The company's success is attributed to its diverse range of test kits in various medical areas, including immunology, infectious diseases, sexually transmitted diseases, gastroenterology, and virology. Additionally, Meridian Bioscience Inc. stays up-to-date with the latest technological advancements in biotechnology to ensure the fast and effective performance of its tests. The company operates globally, collaborating with universities, research institutions, government agencies, and distributors to ensure the worldwide distribution and marketing of its products. In summary, Meridian Bioscience Inc. is an innovative company specializing in the development, manufacture, and distribution of test kits for the diagnosis of infectious diseases and other medical conditions. Its wide range of products, including immunology products, infectious disease diagnostics, sexually transmitted disease test kits, gastroenterology, virology, and molecular diagnostics, coupled with advanced technologies, provides fast, accurate, and reliable diagnostic support. Meridian Bioscience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Meridian Bioscience stock

Change in Working Capital of Meridian Bioscience is 7.59 M USD in 2022.

Change in Working Capital of Meridian Bioscience changed from -19.25 M USD to 7.59 M USD, representing a -139.44% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Change in Working Capital Meridian Bioscience since 2006 – with annual values, charts, and detailed analysis.

Change in working capital reflects the period-over-period change in current assets minus current liabilities. It impacts operating cash flow significantly.

Change in Working Capital's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Change in Working Capital's Meridian Bioscience historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Meridian Bioscience

All Key Metrics — Meridian Bioscience